Marker Therapeutics Inc.
08/17/2021 | Press release | Archived content
Correspondence (SEC Filing - CORRESP)
Marker Therapeutics, Inc.
3200 Southwest Freeway, Suite 2500
Houston, Texas 77027
August 17, 2021
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Lauren S. Hamill | |
| Re: | Marker Therapeutics, Inc. | |
| Registration Statement on Form S-3 (File No. 333-258687) | ||
| Request for Acceleration of Effective Date |
Ms. Hamill:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the 'Registrant') hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-258687) (the 'Registration Statement') to become effective on August 19, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Owen Williams at (202) 842-7843.
[Signature page follows]
| Very truly yours, | ||
| Marker Therapeutics Inc. | ||
| By: | /s/ Peter Hoang | |
| Peter Hoang | ||
| President and Chief Executive Officer |
| cc: | |
|
Anthony Kim, Marker Therapeutics, Inc. Michael Loiacono, Marker Therapeutics, Inc. |
|
| Divakar Gupta, Cooley LLP | |
| Darren DeStefano, Cooley LLP | |
| Owen Williams, Cooley LLP |
Signature Page to Company Acceleration Request - S-3